Form 4: Tempest Therapeutics Director Granted Stock Options

Tempest Therapeutics director Ronit Simantov was granted 1,230 stock options with an exercise price of $2.94, vesting by early 2027.

Summary

• Ronit Simantov, a Director at Tempest Therapeutics, Inc. (TPST), was granted 1,230 stock options.
• The grant date for these options was January 27, 2026.
• Each stock option has an exercise price of $2.94.
• The options are scheduled to vest in full on the earlier of January 27, 2027, or the day of the Issuer's 2026 annual stockholder meeting.
• Vesting is contingent upon Ms. Simantov's continuous service through the vesting date.
• The expiration date for these stock options is January 26, 2036.
• Following this transaction, Ms. Simantov beneficially owns 1,230 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard incentive for a director, aligning their interests with shareholders. It is a routine event and not indicative of significant operational changes.

Positives

• The grant of stock options to Director Ronit Simantov aligns her financial interests with those of the shareholders, incentivizing long-term company performance and strategic oversight.

Risks

• The value of the stock options is subject to the future market price of Tempest Therapeutics, Inc. common stock, which may fluctuate.
• There is a risk that the stock price may not exceed the exercise price of $2.94, rendering the options worthless at expiration.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director Ronit Simantov through at least early 2027, aligning her incentives with the company's long-term performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive and director compensation packages to attract and retain talent and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The structure of this stock option grant, including the vesting schedule and exercise price, is consistent with typical compensation practices for non-employee directors in publicly traded biotechnology companies.
• The number of options granted (1,230) is relatively modest, which is not uncommon for a single director's annual grant, especially in companies of similar market capitalization to Tempest Therapeutics.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ronit Simantov, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest in full on the earlier of January 27, 2027, or the date of the Issuer's 2026 annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Tempest Therapeutics, TPST, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting